PH30685A - Crystalline anhydrous mycrophenolate mofetil and intravenous formulation thereof - Google Patents

Crystalline anhydrous mycrophenolate mofetil and intravenous formulation thereof

Info

Publication number
PH30685A
PH30685A PH48985A PH48985A PH30685A PH 30685 A PH30685 A PH 30685A PH 48985 A PH48985 A PH 48985A PH 48985 A PH48985 A PH 48985A PH 30685 A PH30685 A PH 30685A
Authority
PH
Philippines
Prior art keywords
mofetil
mycrophenolate
crystalline anhydrous
intravenous formulation
crystalline
Prior art date
Application number
PH48985A
Other languages
English (en)
Inventor
Roger C Fu
De-Mei Leung
Jeffrey S Fleitman
Michele C Rizzolio
Andrew R Miksztal
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of PH30685A publication Critical patent/PH30685A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
PH48985A 1993-09-15 1994-09-14 Crystalline anhydrous mycrophenolate mofetil and intravenous formulation thereof PH30685A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12184193A 1993-09-15 1993-09-15

Publications (1)

Publication Number Publication Date
PH30685A true PH30685A (en) 1997-09-16

Family

ID=22399119

Family Applications (1)

Application Number Title Priority Date Filing Date
PH48985A PH30685A (en) 1993-09-15 1994-09-14 Crystalline anhydrous mycrophenolate mofetil and intravenous formulation thereof

Country Status (32)

Country Link
US (2) US5543408A (fi)
EP (1) EP0724581B1 (fi)
JP (1) JP3411038B2 (fi)
KR (1) KR100349772B1 (fi)
CN (1) CN1060770C (fi)
AT (1) ATE173475T1 (fi)
AU (1) AU677435B2 (fi)
BR (1) BR9407469A (fi)
CA (1) CA2171836C (fi)
CZ (1) CZ292423B6 (fi)
DE (1) DE69414720T2 (fi)
DK (1) DK0724581T3 (fi)
ES (1) ES2123831T3 (fi)
FI (1) FI119639B (fi)
HK (1) HK1012624A1 (fi)
HU (1) HU217300B (fi)
IL (1) IL110970A (fi)
LT (1) LT4052B (fi)
LV (1) LV11326B (fi)
MX (1) MXPA94007099A (fi)
NO (1) NO314727B1 (fi)
NZ (1) NZ273801A (fi)
PH (1) PH30685A (fi)
PL (1) PL178522B1 (fi)
RO (2) RO118075B1 (fi)
RU (1) RU2132849C1 (fi)
SG (1) SG55006A1 (fi)
SI (1) SI9420052B (fi)
TW (1) TW370527B (fi)
UA (1) UA49797C2 (fi)
WO (1) WO1995007902A1 (fi)
ZA (1) ZA947088B (fi)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
IN188985B (fi) 1998-12-09 2002-11-30 Biocon Ltd
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds
US20050187170A1 (en) * 2003-06-16 2005-08-25 Biocryst Pharmaceuticals, Inc. Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors
CA2537958C (en) * 2003-09-11 2013-06-11 Sandoz Ag Process for the production of mycophenolate mofetil
EP1740564A2 (en) * 2004-04-26 2007-01-10 Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság Process for preparation of mycophenolic acid and ester derivatives thereof
WO2005105769A2 (en) * 2004-04-27 2005-11-10 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg - Mycophenolate mofetil impurity
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
WO2006012385A2 (en) * 2004-07-20 2006-02-02 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Crystalline mycophenolate sodium
CN100383520C (zh) * 2004-09-20 2008-04-23 复旦大学 一种测定人血浆中霉酚酸及其代谢物的方法
WO2006086498A2 (en) * 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Treatment of vascular, autoimmune and inflammatory diseases using low dosages of impdh inhibitors
WO2006086500A2 (en) * 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Compositions and methods for treating vascular, autoimmune and inflammatory diseases
US20080281111A1 (en) * 2005-04-26 2008-11-13 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
WO2008000418A2 (en) 2006-06-27 2008-01-03 Sandoz Ag New method for salt preparation
CN101953807A (zh) * 2010-10-09 2011-01-26 山西普德药业有限公司 一种注射用吗替麦考酚酯冻干粉针剂及其制备方法
SG11201507371RA (en) 2013-03-14 2015-10-29 Alkermes Pharma Ireland Ltd Prodrugs of fumarates and their use in treating various deseases
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US9168246B2 (en) 2013-06-27 2015-10-27 Veloxis Pharmaceutical A/S Regimen for suppressing organ rejection
CA2940845C (en) 2014-02-24 2019-09-24 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
WO2018167628A1 (en) 2017-03-13 2018-09-20 Ftf Pharma Private Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
WO2020039263A2 (en) 2018-08-18 2020-02-27 Ftf Pharma Private Limited Pharmaceutical suspension for oral dosage
WO2022187379A1 (en) 2021-03-03 2022-09-09 Sana Biotechnology, Inc. Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328213A (en) * 1979-11-28 1982-05-04 Schering Corporation Stable injectable labetalol formulation
US4478829A (en) * 1983-04-28 1984-10-23 Armour Pharmaceutical Company Pharmaceutical preparation containing purified fibronectin
US4753935A (en) * 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions

Also Published As

Publication number Publication date
US5545637A (en) 1996-08-13
FI961169A (fi) 1996-03-13
WO1995007902A1 (en) 1995-03-23
HUT75119A (en) 1997-04-28
CN1131420A (zh) 1996-09-18
EP0724581A1 (en) 1996-08-07
SI9420052A (en) 1996-12-31
UA49797C2 (uk) 2002-10-15
NZ273801A (en) 1997-10-24
NO314727B1 (no) 2003-05-12
PL178522B1 (pl) 2000-05-31
CZ292423B6 (cs) 2003-09-17
KR100349772B1 (ko) 2002-12-28
CA2171836A1 (en) 1995-03-23
SI9420052B (sl) 2004-02-29
CN1060770C (zh) 2001-01-17
HK1012624A1 (en) 1999-08-06
HU9600652D0 (en) 1996-05-28
DE69414720T2 (de) 1999-04-08
JP3411038B2 (ja) 2003-05-26
EP0724581B1 (en) 1998-11-18
BR9407469A (pt) 1996-11-12
RU2132849C1 (ru) 1999-07-10
CZ78896A3 (en) 1996-10-16
LV11326A (lv) 1996-06-20
JPH09502721A (ja) 1997-03-18
PL313480A1 (en) 1996-07-08
ATE173475T1 (de) 1998-12-15
MXPA94007099A (es) 2004-01-23
FI119639B (fi) 2009-01-30
FI961169A0 (fi) 1996-03-13
US5543408A (en) 1996-08-06
RO118427B1 (ro) 2003-05-30
CA2171836C (en) 2006-11-14
ZA947088B (en) 1996-03-14
LT96028A (en) 1996-08-26
NO961075D0 (no) 1996-03-15
IL110970A (en) 1999-01-26
LT4052B (en) 1996-10-25
NO961075L (no) 1996-03-15
SG55006A1 (en) 1998-12-21
RO118075B1 (ro) 2003-01-30
IL110970A0 (en) 1994-11-28
AU677435B2 (en) 1997-04-24
TW370527B (en) 1999-09-21
HU217300B (hu) 1999-12-28
DK0724581T3 (da) 1999-08-02
ES2123831T3 (es) 1999-01-16
LV11326B (en) 1996-10-20
DE69414720D1 (de) 1998-12-24
AU7723894A (en) 1995-04-03

Similar Documents

Publication Publication Date Title
HK1012624A1 (en) Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof
IL111365A (en) (R)-5-carbamoyl-8-fluoro-3-N,N-disubstituted-amino-3,4-dihydro-2H-1-benzopyrans their preparation and pharmaceutical compositions containing them
CA2171275A1 (en) Stilbene derivatives and pharmaceutical compositions containing them
MY100359A (en) External pharmaceutical composition.
MY121908A (en) 3-amidopyrazole derivatives, process for preparing these and pharmaceutical compositions containing them.
HK1003708A1 (en) Peripheral vasodilating agent containing n-acylated 4-amino piperidine derivatives as active ingredients
CA2108903A1 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
ZA922297B (en) Crystalline tiababine monohydrate,its preparation and use
CA2063273A1 (en) Surfactant compositions and methods
ATE35812T1 (de) Gamma-butyrolactonderivate, verfahren zur herstellung derselben und dieselben als aktive bestandteile enthaltende immunomodulierende zubereitungen.
TW252979B (fi)
WO1990003172A3 (en) Bile acids for treatment of viral infections
GEP20033054B (en) 2,4,4-Trisubstituted-1,3-Dioxolane Antifungals
MX9600165A (es) 3-alcoxicarbonil-tiadiazinonas, proceso para su preparacion y composiciones farmaceuticas que las contienen.
EP0127389A3 (en) N,n-diethyl-5-methyl-2h-1-benzothiopyrano-(4,3,2-cd)-indazole-2-ethanamine, compositions comprising the same and uses therefor
EP0583480A4 (en) MEANS TO REDUCE SIDE EFFECTS.
EP0733364A4 (en) MIDIZINAL PREPARATION FOR THE CIRCUIT SYSTEM
HUT66204A (en) Phytoactive compositions containing n-phosphonomethyl-clycine monoammonium salts as active ingredients and process for producing the compositions and the active ingredients